Norbert W.  Bischofberger net worth and biography

Norbert Bischofberger Biography and Net Worth

CEO of Kronos Bio
Norbert joined Kronos Bio in 2018 as President and CEO. Prior to joining Kronos Bio, Norbert was the Executive Vice President, Research and Development and Chief Scientific Officer at Gilead Sciences. Norbert joined Gilead in 1990 as Director of Chemistry after having worked as a Senior Scientist in Genentech’s DNA Synthesis Group from 1986 until 1990. During his 28-year tenure at Gilead, Norbert presided over the development and approval of more than 25 medicines for a range of serious conditions which led the transformation of the treatment of diseases such as HIV, HCV and lymphoma. Norbert was part of the core management team that grew Gilead from less than 50 employees with no revenues to 10,000 employees with $25B in revenue. Norbert received a Ph.D. in organic chemistry from Zurich’s Eidgenössische Technische Hochschule and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts. Norbert received an honorary doctorate in Natural Sciences (2016) from The University of Innsbruck and an honorary doctorate in Letters in Medicine (2017) from Baylor College of Medicine. Norbert was elected a Fellow of The American Association for Advancement of Science (2018). In addition to Kronos Bio, Norbert serves on the Supervisory Board of Bayer AG and Board of Directors of Morphic Therapeutic.

What is Norbert W. Bischofberger's net worth?

The estimated net worth of Norbert W. Bischofberger is at least $2.59 million as of November 15th, 2023. Dr. Bischofberger owns 2,180,297 shares of Kronos Bio stock worth more than $2,594,771 as of November 29th. This net worth estimate does not reflect any other investments that Dr. Bischofberger may own. Additionally, Dr. Bischofberger receives a salary of $809,700.00 as CEO at Kronos Bio. Learn More about Norbert W. Bischofberger's net worth.

How old is Norbert W. Bischofberger?

Dr. Bischofberger is currently 67 years old. There are 6 older executives and no younger executives at Kronos Bio. Learn More on Norbert W. Bischofberger's age.

What is Norbert W. Bischofberger's salary?

As the CEO of Kronos Bio, Inc., Dr. Bischofberger earns $809,700.00 per year. Learn More on Norbert W. Bischofberger's salary.

How do I contact Norbert W. Bischofberger?

The corporate mailing address for Dr. Bischofberger and other Kronos Bio executives is , , . Kronos Bio can also be reached via phone at 650-781-5200 and via email at [email protected]. Learn More on Norbert W. Bischofberger's contact information.

Has Norbert W. Bischofberger been buying or selling shares of Kronos Bio?

Over the course of the past ninety days, Norbert W. Bischofberger has bought $1,202,320.20 of Kronos Bio stock. Most recently, on Friday, November 17th, Norbert W. Bischofberger bought 97,935 shares of Kronos Bio stock. The stock was acquired at an average cost of $1.08 per share, with a total value of $105,769.80. Following the completion of the transaction, the chief executive officer now directly owns 2,540,665 shares of the company's stock, valued at $2,743,918.20. Learn More on Norbert W. Bischofberger's trading history.

Who are Kronos Bio's active insiders?

Kronos Bio's insider roster includes Norbert Bischofberger (CEO), Marianne De Backer (Director), Jorge DiMartino (VP), Christopher Dinsmore (Insider), and Jakob Loven (Director). Learn More on Kronos Bio's active insiders.

Are insiders buying or selling shares of Kronos Bio?

During the last year, Kronos Bio insiders bought shares 2 times. They purchased a total of 1,468,623 shares worth more than $1,202,320.20. During the last year, insiders at the sold shares 8 times. They sold a total of 80,334 shares worth more than $141,997.50. The most recent insider tranaction occured on November, 17th when CEO Norbert W Bischofberger bought 97,935 shares worth more than $105,769.80. Insiders at Kronos Bio own 23.4% of the company. Learn More about insider trades at Kronos Bio.

Information on this page was last updated on 11/17/2023.

Norbert W. Bischofberger Insider Trading History at Kronos Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2023Buy97,935$1.08$105,769.802,540,665View SEC Filing Icon  
11/15/2023Buy1,370,688$0.80$1,096,550.402,180,297View SEC Filing Icon  
5/19/2022Buy300,000$3.78$1,134,000.00809,609View SEC Filing Icon  
5/17/2022Buy90,931$3.83$348,265.73303,411View SEC Filing Icon  
12/6/2021Buy14,356$12.09$173,564.04View SEC Filing Icon  
10/14/2020Buy95,500$19.00$1,814,500.00View SEC Filing Icon  
See Full Table

Norbert W. Bischofberger Buying and Selling Activity at Kronos Bio

This chart shows Norbert W Bischofberger's buying and selling at Kronos Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kronos Bio Company Overview

Kronos Bio logo
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $1.18
Low: $1.18
High: $1.25

50 Day Range

MA: $1.06
Low: $0.75
High: $1.30

2 Week Range

Now: $1.18
Low: $0.73
High: $2.84


64,823 shs

Average Volume

298,132 shs

Market Capitalization

$68.81 million

P/E Ratio


Dividend Yield